{"id":112717,"date":"2022-07-14T09:27:49","date_gmt":"2022-07-14T09:27:49","guid":{"rendered":"https:\/\/euretina.org\/?post_type=resource&p=112717"},"modified":"2022-08-15T22:41:03","modified_gmt":"2022-08-15T22:41:03","slug":"free-paper-session-ird-i","status":"publish","type":"resource","link":"https:\/\/euretina.org\/resource\/free-paper-session-ird-i\/","title":{"rendered":"Free Paper Session 1: IRD I"},"content":{"rendered":"\n
\n\n\n\t
\n\t\t\t\t
\n\t\t\t\n\t\t\t\n\n

Time & Date:<\/strong> 1 September, 14:45 – 15:45 CEST
Chairpersons:<\/strong> D. Fischer UK <\/em>& I. Audo FRANCE<\/em><\/p>\n\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n

\n\n\n\t
\n\t\t\t\t
\n\t\t\t\n\t\t\t\n\n\t
\n\t\t\n\n

Speakers:<\/strong><\/p>\n\t\t\t<\/div>\n\t\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t

\n\t\t\t\t
\n\t\t\t\n\t\t\t\n\n\t
\n\t\t\n\n

Presentations:<\/strong><\/p>\n\t\t\t<\/div>\n\t\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t

\n\t\t\t\t
\n\t\t\t\n\t\t\t\n\n\t
\n\t\t\n\n

Speakers & Presentations:<\/strong><\/p>\n\t\t\t<\/div>\n\t\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n

\n\n\n\t
\n\t\t\t\t
\n\t\t\t\n\t\t\t\n\n

I. Audo FRANCE<\/em><\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t

\n\t\t\t\t
\n\t\t\t\n\t\t\t\n\n

14:45 <\/em>Welcome<\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n

\n\n\n\t
\n\t\t\t\t
\n\t\t\t\n\t\t\t\n\n

N. Paudel IRELAND<\/em><\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t

\n\t\t\t\t
\n\t\t\t\n\t\t\t\n\n

14:47 <\/em>Genetic testing experiences of people living with inherited retinal diseases (IRDs) \u2013 results of a global survey<\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n

\n\n\n\t
\n\t\t\t\t
\n\t\t\t\n\t\t\t\n\n

I. Audo FRANCE<\/em><\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t

\n\t\t\t\t
\n\t\t\t\n\t\t\t\n\n

14:53<\/em> RLIGHT – Observational study on the use of voretigene neparvovec (VN) in patients with inherited retinal dystrophy (IRD) at CHNO des Quinze-Vingts: a 1-year follow-up safety and efficacy results<\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n

\n\n\n\t
\n\t\t\t\t
\n\t\t\t\n\t\t\t\n\n

D. Fischer UK<\/em><\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t

\n\t\t\t\t
\n\t\t\t\n\t\t\t\n\n

14:59<\/em> Real-world safety and effectiveness of voretigene neparvovec: Year 2 interim results from the PERCEIVE study<\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n

\n\n\n\t
\n\t\t\t\t
\n\t\t\t\n\t\t\t\n\n

V. Gonzalez USA<\/em><\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t

\n\t\t\t\t
\n\t\t\t\n\t\t\t\n\n

15:05<\/em> Development of Novel Endpoints for the Study of Multi-Characteristic Opsin Enabled Vision Restoration in Patients with Advanced Retinitis Pigmentosa; Double-masked, Randomized, sham-controlled, Multicenter Phase 2b study<\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n

\n\n\n\t
\n\t\t\t\t
\n\t\t\t\n\t\t\t\n\n

J. Wawrzynski UK<\/em><\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t

\n\t\t\t\t
\n\t\t\t\n\t\t\t\n\n

15:11 <\/em>Intravitreal Cerliponase alfa for the treatment of Neuronal Ceroid Lipofuscinosis type 2 (CLN2) related retinal dystrophy: A first in man report of ocular enzyme replacement.<\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n

\n\n\n\t
\n\t\t\t\t
\n\t\t\t\n\t\t\t\n\n

S.N Geada Batista PORTUGAL<\/em><\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t

\n\t\t\t\t
\n\t\t\t\n\t\t\t\n\n

15:17 <\/em>Expanding the mutational spectrum of CNGB1-associated RP-olfactory dysfunction syndrome<\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n

\n\n\n\t
\n\t\t\t\t
\n\t\t\t\n\t\t\t\n\n

L. Mautone GERMANY<\/em><\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t

\n\t\t\t\t
\n\t\t\t\n\t\t\t\n\n

15:23<\/em> Diurnal changes of macular anatomy and sensitivity in X-linked juvenile retinoschisis<\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n

\n\n\n\t
\n\t\t\t\t
\n\t\t\t\n\t\t\t\n\n

H. Baran \u00d6zdemir TURKEY<\/em><\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t

\n\t\t\t\t
\n\t\t\t\n\t\t\t\n\n

15:29<\/em> Congenital X-Linked Retinoschisis: Surgical Needs and Outcomes in Long Term. A Retrospective Multicenter International Study<\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n

\n\n\n\t
\n\t\t\t\t
\n\t\t\t\n\t\t\t\n\n

M. Mateos SPAIN<\/em><\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t

\n\t\t\t\t
\n\t\t\t\n\t\t\t\n\n

15:35<\/em> Hair cortisol level as a molecular biomarker in retinitis pigmentosa patients<\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n

\n\n\n\t
\n\t\t\t\t
\n\t\t\t\n\t\t\t\n\n

All Faculty<\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t

\n\t\t\t\t
\n\t\t\t\n\t\t\t\n\n

15:41<\/em> Discussion<\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n

\n\n\n\t
\n\t\t\t\t
\n\t\t\t\n\t\t\t\n\n\t
\n\t\t\n\n
See full interactive programme<\/strong><\/a><\/div>\n
Programme details may be subject to change. Please refer to the interactive programme for the most up to date details. <\/em><\/div>\n\t\t\t<\/div>\n\t\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n\n","protected":false},"excerpt":{"rendered":"

Free Paper Session: IRD I<\/p>\n","protected":false},"author":1,"featured_media":95529,"template":"","categories":[1609],"tags":[2955,179,1610],"session_type":[],"event":[],"subject_disease":[],"section":[],"speaker":[],"resource_type":[199],"acf":[],"_links":{"self":[{"href":"https:\/\/euretina.org\/wp-json\/wp\/v2\/resource\/112717"}],"collection":[{"href":"https:\/\/euretina.org\/wp-json\/wp\/v2\/resource"}],"about":[{"href":"https:\/\/euretina.org\/wp-json\/wp\/v2\/types\/resource"}],"author":[{"embeddable":true,"href":"https:\/\/euretina.org\/wp-json\/wp\/v2\/users\/1"}],"version-history":[{"count":11,"href":"https:\/\/euretina.org\/wp-json\/wp\/v2\/resource\/112717\/revisions"}],"predecessor-version":[{"id":116826,"href":"https:\/\/euretina.org\/wp-json\/wp\/v2\/resource\/112717\/revisions\/116826"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/euretina.org\/wp-json\/wp\/v2\/media\/95529"}],"wp:attachment":[{"href":"https:\/\/euretina.org\/wp-json\/wp\/v2\/media?parent=112717"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/euretina.org\/wp-json\/wp\/v2\/categories?post=112717"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/euretina.org\/wp-json\/wp\/v2\/tags?post=112717"},{"taxonomy":"session_type","embeddable":true,"href":"https:\/\/euretina.org\/wp-json\/wp\/v2\/session_type?post=112717"},{"taxonomy":"event","embeddable":true,"href":"https:\/\/euretina.org\/wp-json\/wp\/v2\/event?post=112717"},{"taxonomy":"subject_disease","embeddable":true,"href":"https:\/\/euretina.org\/wp-json\/wp\/v2\/subject_disease?post=112717"},{"taxonomy":"section","embeddable":true,"href":"https:\/\/euretina.org\/wp-json\/wp\/v2\/section?post=112717"},{"taxonomy":"speaker","embeddable":true,"href":"https:\/\/euretina.org\/wp-json\/wp\/v2\/speaker?post=112717"},{"taxonomy":"resource_type","embeddable":true,"href":"https:\/\/euretina.org\/wp-json\/wp\/v2\/resource_type?post=112717"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}